Neuberger Berman Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Neuberger Berman Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-12,500	Closed	-$1.95M	–	1683
2020 Q2	$1.95M	Hold	12,500	–	–	﹤0.01%	1003
2020 Q1	$1.8M	Hold	12,500	–	–	﹤0.01%	968
2019 Q4	$2.56M	Buy	12,500 +1,300	+12%	+$237K	﹤0.01%	978
2019 Q3	$899K	Buy	11,200 +4,300	+62%	+$365K	﹤0.01%	1172
2019 Q2	$651K	Buy	6,900 +2,900	+73%	+$250K	﹤0.01%	1240
2019 Q1	$342K	Buy	+4,000	New	+$332K	﹤0.01%	1340

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Neuberger Berman Group's RETA Position: Q3 2020 in Review

Neuberger Berman Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 12,500 shares — an estimated $1.95M sold.

Neuberger Berman Group first reported a position in RETA in Q1 2019 and held it in 6 quarters. The position peaked at $2.56M in Q4 2019. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

Neuberger Berman Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
Neuberger Berman Group sold 12,500 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $1.95M.
Neuberger Berman Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 6 quarters.
Neuberger Berman Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.56M in Q4 2019.
186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Neuberger Berman Group's 13F filing for Q3 2020, filed 12 Nov 2020.